FDA clears Amgen’s Prolia for glucocorticoid osteoporosis

US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
Read the full story: PharmaTimes: News RSS